Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.540
-0.026 (-1.69%)
Aug 25, 2025, 4:00 PM - Market closed
Cocrystal Pharma Employees
Cocrystal Pharma had 11 employees as of December 31, 2024. The number of employees decreased by 1 or -8.33% compared to the previous year.
Employees
11
Change (1Y)
-1
Growth (1Y)
-8.33%
Revenue / Employee
n/a
Profits / Employee
-$1,141,909
Market Cap
15.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 11 | -1 | -8.33% |
Dec 31, 2023 | 12 | 0 | - |
Dec 31, 2022 | 12 | -1 | -7.69% |
Dec 31, 2021 | 13 | 0 | - |
Dec 31, 2020 | 13 | 2 | 18.18% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
COCP News
- 11 days ago - Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 20 days ago - Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference - GlobeNewsWire
- 6 weeks ago - Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference - GlobeNewsWire
- 2 months ago - Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain - GlobeNewsWire
- 3 months ago - Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 4 months ago - Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants - GlobeNewsWire